BZ vs RCUS vs AGEN vs EXEL vs INCY

For growth investors, Kanzhun Limited (BZ) is the stronger pick with 23.

6% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). Incyte Corporation (INCY) offers the better valuation at 14. 9x trailing P/E (12. 7x forward), making it the more compelling value choice. Analysts rate Kanzhun Limited (BZ) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Incyte Corporation (INCY) is the cheapest at 14.

9x versus Kanzhun Limited at 27. 2x. On forward P/E, Kanzhun Limited is actually cheaper at 1. 6x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Exelixis, Inc.

(EXEL) delivered a total return of +98. 6%, compared to -94. 5% for Agenus Inc. (AGEN). Over 10 years, the gap is even starker: EXEL returned +813. 1% versus AGEN's -95. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Incyte Corporation (INCY) is the lower-risk stock at 0.

87β versus Agenus Inc. 's 2. 30β — meaning AGEN is approximately 165% more volatile than INCY relative to the S&P 500. On balance sheet safety, Incyte Corporation (INCY) carries a lower debt/equity ratio of 1% versus 16% for Arcus Biosciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Kanzhun Limited (BZ) is pulling ahead at 23.

6% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: Incyte Corporation grew EPS 41. 7% year-over-year, compared to -4. 8% for Arcus Biosciences, Inc.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Exelixis, Inc.

(EXEL) is the more profitable company, earning 33. 7% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps 33. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EXEL leads at 37. 6% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — EXEL leads at 96. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Kanzhun Limited (BZ) trades at 1.

6x forward P/E versus 14. 4x for Exelixis, Inc. — 12. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AGEN: 104. 7% to $7. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Exelixis, Inc.

(EXEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 88), +813. 1% 10Y return). Agenus Inc. (AGEN) carries a higher beta of 2. 30 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXEL: +813. 1%, AGEN: -95. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BZ (Industrials) and RCUS (Healthcare) and AGEN (Healthcare) and EXEL (Healthcare) and INCY (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BZ is a mid-cap high-growth stock; RCUS is a small-cap quality compounder stock; AGEN is a small-cap quality compounder stock; EXEL is a mid-cap quality compounder stock; INCY is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.